Importantly, our BC clinical data and preclinical data suggest that TIM3 plays a more relevant role in metastatic tumor cells rather than in immune cells, supporting the use of TIM3 blockade to target tumor cells to prevent metastatic relapse. The gene discussed is HAVCR2; the disease is neoplasm.